Ford to slash 12,000 jobs in Europe, restructuring plans in pipeline
By Nikita Chaurasia  Date: 2019-06-29

Ford to slash 12,000 jobs in Europe, restructuring plans in pipeline

Ford Motor Company, the US-based multinational automaker recently announced to restructure its European operations to shift focus on commercial vehicles sector & the sale of SUVs. The restructuring exercise involves loss of 12,000 jobs – the announcement of which has been done already.

As per sources close to the matter, Ford plans to sell or close six of its European facilities. Europe was not exactly a money-spinner for Ford last year, due to decline in demand, similar to many other regions, though the demand was consistent in North America. The overall restructuring will result in improvement in the company’s financial results in Europe for 2019, Ford claimed.

Reportedly, the restructuring includes formation of 3 new business groups- passenger vehicles, commercial vehicles & imports. The company is a European market leader in pickups & vans and is expecting to double its profitability in the same within the next 5 years. Ford also has plans to push its passenger vehicle business in Europe, along with tripling its imports in this segment by 2024.

Ford seems to be targeting the SUV sector, promising 3 new models, in next 5 years (all of which will come with an electrified variant). An integrated collection of battery electric vehicles will soon be assembled in Europe.

Ford recently unveiled a new compact SUV- Puma, for the European market, based on same small-car platform as the Fiesta. The aim of introducing Puma is to draw customers away from the compact SUVs being sold by European brands, such as- Peugeot and Renault, also from premium compact-car brands like BMW’s Mini.

In a recent announcement, the company stated that its European cut would result in reduction of its manufacturing facility’s footprint from 24 to 18. Germany, Russia and the U.K. will be the most affected with cut down of 12,000 jobs – the loss means a 22% reduction of European workforce.

Source credits: http://fortune.com/2019/06/27/ford-puma-suv-job-cuts-europe/

About Author

Nikita Chaurasia    

Nikita Chaurasia

An accomplished professional in the field of content development, playing with words comes naturally to Nikita Chaurasia. After completing her post-graduate MBA degree in Advertising and PR, Nikita worked across numerous content-driven verticals, undertaking diverse r...

Read More

More News By Nikita Chaurasia

Fragomen acquires SimpleCitizen to reinforce its immigration services
Fragomen acquires SimpleCitizen to reinforce its immigration services
By Nikita Chaurasia

In a recent turn of events, Fragomen, Del Rey, Bernsen & Loewy, LLP, a leading corporate immigration law company has reportedly joined hands with SimpleCitizen Inc. to form Fragomen Technologies Inc., a new subsidiary which will provide a combina...

Nautilus buys 17 MW portfolio from solar energy developer Pine Gate
Nautilus buys 17 MW portfolio from solar energy developer Pine Gate
By Nikita Chaurasia

Solar project development and asset management major, Nautilus Solar Energy LLC, has reportedly announced its acquisition of two solar portfolios in Rhode Island and Oregon amounting to a total of nearly 17 MW from leading solar energy developer, Pin...

Locate Bio obtains multiple late stage orthobiologics assets from RCSI
Locate Bio obtains multiple late stage orthobiologics assets from RCSI
By Nikita Chaurasia

Regenerative medicine major, Locate Bio, has reportedly announced its in-licensing of several late stage orthobiologics assets from the RCSI University of Medicine and Health Sciences. Sources state that the technologies created by the RCSI Tissue E...

Roche acquires Inflazome to gain control over inflammatory treatments
Roche acquires Inflazome to gain control over inflammatory treatments
By Nikita Chaurasia

In a recent turn of events, Swiss healthcare giant, F. Hoffmann-La Roche AG has reportedly acquired an Irish biotech firm Inflazome Ltd. for approximately USD 451 million (€380 million). As per the agreement, Roche will acquire complete rights ...

Innovent, Eli Lilly release results of ORIENT-11 trial for lung cancer
Innovent, Eli Lilly release results of ORIENT-11 trial for lung cancer
By Nikita Chaurasia

Innovent Biologics Inc., in collaboration with American pharmaceutical giant Eli Lilly and Company, have reportedly announced that the biomarker results of ORIENT-11 trials which were displayed during a mini verbal presentation at ESMO (European Soci...